Dynamic fluorescence imaging for the detection of vascular changes in anti-angiogenic drug therapy

Optics InfoBase Conference Papers

Volumn , Issue , 2010, Pages

  Lee, Jonghwan ^a   Pöschinger, Thomas ^c   Hernandez, Sonia L ^b   Huang, Jianzhong ^b   Johung, Tessa ^b   Kandel, Jessica ^b   Yamashiro, Darrell J ^b   Hielscher, Andreas H ^a,b  

^a 351 Engineering Terrace ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGIOGENIC; FLUORESCENCE IMAGING; INDOCYANINE GREEN; SMALL ANIMAL; VASCULATURE;

COMPUTER GENERATED HOLOGRAPHY; FLUORESCENCE; IMAGING SYSTEMS;

DRUG THERAPY;

EID: 84897731681     PISSN: None     EISSN: 21622701     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (10)

1. C. Sessa, A. Guibal, G. D. Conte, C. Rüegg, "Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology:tools or decorations? "Nature Clinical Practice Oncology, Vol 5, No 7(2008)
2. Y.R. Kim, A. Yudina, J. Figueiredo, W. Reichardt, D. Hu-Lowe, A. Petrovsky, H.W. Kang, D Torres, U. Mahmood, R. Wissleder, A. A. Bogdanov, Jr. "Detection of Early Antiangiogenic Effects in Human Colon Adenocarcinoma Xenografts: In vivo Changes of Tumor Blood Volume in Response to Experimental VEGFR Tyrosine Kinase Inhibitor "Cancer Res 2005; 65:(20) (2005)
3. F. Kabbinavar, H.I. Hurwitz, L.Fehrenbacher, N.. Meropol, W.F. Novotny, G. Lieberman, S. Griffing, E. Bergsland, "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer," J. Clin. Oncol. 21,pp. 60-65 (2003).
4. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," N. Engl. J. Med. 350, pp. 2335-2342 (2004).
5. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, N. Ferrara, "Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo," Nature 362, pp. 841-844 (1993).
6. N.R. Smith, N.H. James, I. Oakley, A. Wainwright, C. Copley, J. Kendrew, et al, "Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts," Molecular Cancer Therapeutics 6, pp. 2198-2208 (2007).
7. D.W. Miller, S. Vosseler, N. Mirancea, D.J. Hicklin, P. Bohlen, H.E. Volcker, F.G. Holz and N.E. Fusenig, "Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants," American Journal of Pathology 167(5), pp. 1389-1403 (2005).
8. V. Saxena, M. Sadoqu, J. Shao "Polymeric nanoparticulate delivery system for indocyanine green: Biodistribution in healthy mice" international journal of Pharmaceutics 308, 200-203 (2006).
9. E.M.C. Hillman, A. Moore "All-optical anatomical co-registration for molecular imaging of small animals using dynamic contrast "Nature photonics, vol 1(2007)
10. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, R.K. Jain, "Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors", Cancer Research 64, 3731-3736 (2004).